Sex Differences in the Impact of Coexistent Diabetes on Survival in Patients With Coronary Heart Disease

Diabetes Care ◽  
1993 ◽  
Vol 16 (5) ◽  
pp. 708-713 ◽  
Author(s):  
Y. Liao ◽  
R. S. Cooper ◽  
J. K. Ghali ◽  
D. Lansky ◽  
G. Cao ◽  
...  
Circulation ◽  
2015 ◽  
Vol 131 (suppl_1) ◽  
Author(s):  
Catherine Kim ◽  
Mary Cushman ◽  
Yulia Khodneva ◽  
Lynda D Lisabeth ◽  
Suzanne Judd ◽  
...  

Introduction: Men have greater risk of coronary heart disease (CHD) compared to women. It is unclear whether type of menopause affects this sex difference and if the impact is similar in blacks and whites. Moreover, women and their physicians may consider CHD risk when considering whether elective hysterectomy and/or bilateral salpingo-oophorectomy (BSO) are performed. Hypotheses: Women who undergo natural menopause, menopause due to BSO, and menopause due to hysterectomy alone have different risks of non-fatal CHD and acute CHD death compared to men. Methods: Participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort between 2003 and 2007 without CHD at baseline (n=23,086), with follow-up through December 2011. Cox proportional hazard models were used to calculate the hazard of incident CHD events in men vs. women by menopause type, stratified by black vs. white race. The main outcome measure was adjudicated incident CHD events, defined as nonfatal CHD (definite or probably myocardial infarction) and acute CHD death. Results: Over a median 6.0 years of follow-up, 892 incident CHD events occurred. Cox regression models adjusted for age, age at last menstrual period < 45 years, region, education level, income, CHD risk factors (total cholesterol, high-density lipoprotein, smoking, systolic blood pressure, diabetes, albumin to creatinine ratio, physical activity, C-reactive protein, body mass index and waist circumference), and use of anti-hypertensive medications, statins, and estrogen therapy. Associations of menopause with non-fatal events differed by race (p for interaction=0.03). Among white women, natural menopause (hazard ratio [HR] 0.45, 95% CI 0.31, 0.66) and surgical menopause (HR 0.65, 95% CI 0.42, 0.99) were associated with a reduced hazard of non-fatal events compared to white men. Among black women, natural menopause was marginally significantly associated with lower hazard of non-fatal events compared to men (HR 0.69, 95% CI 0.47, 1.03) but surgical menopause was not (HR 0.81, 95% CI 0.51, 1.29). For acute CHD death, women had lower risk than men regardless of their menopause type and race. Conclusions and Relevance: Sex differences in the risk of incident CHD events were larger among whites than blacks and varied by type of menopause. Women consistently had a lower risk of incident CHD death than men, but the magnitude of sex differences was greater in whites than blacks for non-fatal events regardless of menopause type. Menopause type was not associated with large differences in the hazard for CHD risk.


2007 ◽  
Vol 21 (4) ◽  
pp. 362-372 ◽  
Author(s):  
Nizal Sarrafzadegan ◽  
Katayoun Rabiei ◽  
Shahin Shirani ◽  
Ali Kabir ◽  
Noushin Mohammadifard ◽  
...  

2007 ◽  
Vol 45 (1) ◽  
pp. 3-8 ◽  
Author(s):  
Sadik A. Khuder ◽  
Sheryl Milz ◽  
Timothy Jordan ◽  
James Price ◽  
Kathi Silvestri ◽  
...  

2017 ◽  
Vol 31 (1) ◽  
pp. 165-184 ◽  
Author(s):  
Sharon M. Cruise ◽  
John Hughes ◽  
Kathleen Bennett ◽  
Anne Kouvonen ◽  
Frank Kee

Objective: The aim of this study is to examine the prevalence of coronary heart disease (CHD)–related disability (hereafter also “disability”) and the impact of CHD risk factors on disability in older adults in the Republic of Ireland (ROI) and Northern Ireland (NI). Method: Population attributable fractions were calculated using risk factor relative risks and disability prevalence derived from The Irish Longitudinal Study on Ageing and the Northern Ireland Health Survey. Results: Disability was significantly lower in ROI (4.1% vs. 8.8%). Smoking and diabetes prevalence rates, and the fraction of disability that could be attributed to smoking (ROI: 6.6%; NI: 6.1%), obesity (ROI: 13.8%; NI: 11.3%), and diabetes (ROI: 6.2%; NI: 7.2%), were comparable in both countries. Physical inactivity (31.3% vs. 54.8%) and depression (10.2% vs. 17.6%) were lower in ROI. Disability attributable to depression (ROI: 16.3%; NI: 25.2%) and physical inactivity (ROI: 27.5%; NI: 39.9%) was lower in ROI. Discussion: Country-specific similarities and differences in the prevalence of disability and associated risk factors will inform public health and social care policy in both countries.


Circulation ◽  
2017 ◽  
Vol 135 (suppl_1) ◽  
Author(s):  
Elizabeth J Bell ◽  
Jennifer L St. Sauver ◽  
Veronique L Roger ◽  
Nicholas B Larson ◽  
Hongfang Liu ◽  
...  

Introduction: Proton pump inhibitors (PPIs) are used by an estimated 29 million Americans. PPIs increase the levels of asymmetrical dimethylarginine, a known risk factor for cardiovascular disease (CVD). Data from a select population of patients with CVD suggest that PPI use is associated with an increased risk of stroke, heart failure, and coronary heart disease. The impact of PPI use on incident CVD is largely unknown in the general population. Hypothesis: We hypothesized that PPI users have a higher risk of incident total CVD, coronary heart disease, stroke, and heart failure compared to nonusers. To demonstrate specificity of association, we additionally hypothesized that there is not an association between use of H 2 -blockers - another commonly used class of medications with similar indications as PPIs - and CVD. Methods: We used the Rochester Epidemiology Project’s medical records-linkage system to identify all residents of Olmsted County, MN on our baseline date of January 1, 2004 (N=140217). We excluded persons who did not grant permission for their records to be used for research, were <18 years old, had a history of CVD, had missing data for any variable included in our model, or had evidence of PPI use within the previous year.We followed our final cohort (N=58175) for up to 12 years. The administrative censoring date for CVD was 1/20/2014, for coronary heart disease was 8/3/2016, for stroke was 9/9/2016, and for heart failure was 1/20/2014. Time-varying PPI ever-use was ascertained using 1) natural language processing to capture unstructured text from the electronic health record, and 2) outpatient prescriptions. An incident CVD event was defined as the first occurrence of 1) validated heart failure, 2) validated coronary heart disease, or 3) stroke, defined using diagnostic codes only. As a secondary analysis, we calculated the association between time-varying H 2 -blocker ever-use and CVD among persons not using H 2 -blockers at baseline. Results: After adjustment for age, sex, race, education, hypertension, hyperlipidemia, diabetes, and body-mass-index, PPI use was associated with an approximately 50% higher risk of CVD (hazard ratio [95% CI]: 1.51 [1.37-1.67]; 2187 CVD events), stroke (hazard ratio [95% CI]: 1.49 [1.35-1.65]; 1928 stroke events), and heart failure (hazard ratio [95% CI]: 1.56 [1.23-1.97]; 353 heart failure events) compared to nonusers. Users of PPIs had a 35% greater risk of coronary heart disease than nonusers (95% CI: 1.13-1.61; 626 coronary heart disease events). Use of H 2 -blockers was also associated with a higher risk of CVD (adjusted hazard ratio [95% CI]: 1.23 [1.08-1.41]; 2331 CVD events). Conclusions: PPI use is associated with a higher risk of CVD, coronary heart disease, stroke and heart failure. Use of a drug with no known cardiac toxicity - H 2 -blockers - was also associated with a greater risk of CVD, warranting further study.


Sign in / Sign up

Export Citation Format

Share Document